Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMPDQ8T)

• Drug Name: AB-103 Drug Info
• Synonyms: Superantigen toxin antagonist (iv/infusion, septic shock/toxic shock), Atox Bio/Hebrew University of Jerusalem

Indication

Disease Entry	ICD 11	Status	REF
Necrotizing soft tissue infection	1B71	Phase 3	[1]

• Cross-matching ID:
  PubChem CID: 16111
  CAS Number: CAS 1980-45-6
  TTD Drug ID: DMPDQ8T

Molecule-Related Drug Atlas

Drug(s) Targeting T-cell-specific surface glycoprotein CD28 (CD28)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Belatacept	DMXLYQF	Kidney transplant rejection	NE84	Approved	[3]
Lulizumab pegol	DMGWZ93	Systemic lupus erythematosus	4A40.0	Phase 2	[4]
REGN5678	DM0Y6WU	Prostate cancer	2C82.0	Phase 1/2	[5]
AU101	DMLAKPI	Osteosarcoma	2B51	Phase 1/2	[6]
REGN5668	DMH1UV5	Ovarian cancer	2C73	Phase 1/2	[7]
SAR442257	DMXD5QP	Malignant neoplasm	2A00-2F9Z	Phase 1	[8]
CD28 and CD137 CAR-T Cells	DMFGQXB	Acute lymphoblastic leukaemia	2A85	Phase 1	[9]
CD19-CAR and CD28-CAR T Cells	DMUR1MN	Acute lymphoblastic leukaemia	2A85	Phase 1	[10]
RO7443904	DMSWZNU	Non-hodgkin lymphoma	2B33.5	Phase 1	[11]
RG6333	DM1BRF2	Non-hodgkin lymphoma	2B33.5	Phase 1	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
T-cell-specific surface glycoprotein CD28 (CD28)	TTQ13FT	CD28_HUMAN	Antagonist	[2]

References

• [1] ClinicalTrials.gov (NCT02469857) Phase III Efficacy and Safety Study of AB103 in the Treatment of Patients With Necrotizing Soft Tissue Infections.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] New developments in immunosuppressive therapy for heart transplantation. Expert Opin Emerg Drugs. 2009 Mar;14(1):1-21.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Clinical pipeline report, company report or official report of Regeneron Pharmaceuticals.
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [7] ClinicalTrials.gov (NCT04590326) Phase 1/2 Study of REGN5668 (MUC16xCD28, a Costimulatory Bispecific) Administered in Combination With Cemiplimab or REGN4018 (MUC16xCD3). U.S.National Institutes of Health.
• [8] Clinical pipeline report, company report or official report of Sanofi.
• [9] ClinicalTrials.gov (NCT02186860) Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With Acute Lymphoblastic Leukemia
• [10] ClinicalTrials.gov (NCT02146924) Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia
• [11] Clinical pipeline report, company report or official report of Genentch
• [12] Clinical pipeline report, company report or official report of Roche